ReviewAdvances in experimental medicine and biology2025
Understanding the Different Microglia Functional States to Modulate Their Activity in Retinal Degeneration.
Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Recent advances in genomic, transcriptomic, and imaging have advanced our understanding of microglia cells and their role in neurodegenerative diseases. These dynamic cells can change into distinct functional subpopulations with unique genetic markers and specialized functions once they migrate to the injury site. The model illustrated in Fig. 23.1 predicts that once the tissue recovers from the injury, the predominant microglia functional state should be the homeostatic state and localize within the retina's inner plexiform layers. However, microglia cells do not return to the predominantly homeostatic functional state during retinal degeneration (von Bernhardi et al., Front Aging Neurosci 7:124, 2015). Studies in animal models suggest that during retinal degeneration, rather than maintaining the homeostatic state, microglia can become dysregulated and remain pro-inflammatory, thus exacerbating tissue damage (Rashid et al., Front Immunol 10:1975, 2019; Wang and Cepko, Front Immunol 13:843558, 2022). To address the increased inflammation and excessive phagocytosis seen in these models, some studies employed the use of genetic and pharmacological methods to deplete retinal microglia (Zhao et al., EMBO Mol Med 7:1179-1197, 2015; Wang et al., J Neurosci 36:2827-2842, 2016). Because of their multiple physiological functions, microglia depletion is not a feasible therapeutic approach to address neuroinflammation. Instead, manipulating microglia functions should take center stage when developing therapies for neuroinflammation. Thus, defining the genetic network that regulates microglia functional states is essential to developing therapies to modulate microglia.
Indexed as
Identifiers
39930186What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.